JP2002543392A5 - - Google Patents

Download PDF

Info

Publication number
JP2002543392A5
JP2002543392A5 JP2000614054A JP2000614054A JP2002543392A5 JP 2002543392 A5 JP2002543392 A5 JP 2002543392A5 JP 2000614054 A JP2000614054 A JP 2000614054A JP 2000614054 A JP2000614054 A JP 2000614054A JP 2002543392 A5 JP2002543392 A5 JP 2002543392A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000614054A
Other versions
JP4585693B2 (ja
JP2002543392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/010463 external-priority patent/WO2000065366A1/en
Publication of JP2002543392A publication Critical patent/JP2002543392A/ja
Publication of JP2002543392A5 publication Critical patent/JP2002543392A5/ja
Application granted granted Critical
Publication of JP4585693B2 publication Critical patent/JP4585693B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000614054A 1999-04-22 2000-04-19 Ｉｉ型糖尿病を発現する危険性のｎｍｒによる決定方法 Expired - Fee Related JP4585693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13061299P 1999-04-22 1999-04-22
US60/130,612 1999-04-22
PCT/US2000/010463 WO2000065366A1 (en) 1999-04-22 2000-04-19 Nmr-method for determining the risk of developing type 2 diabetes

Publications (3)

Publication Number Publication Date
JP2002543392A JP2002543392A (ja) 2002-12-17
JP2002543392A5 true JP2002543392A5 (ja) 2007-06-21
JP4585693B2 JP4585693B2 (ja) 2010-11-24

Family

ID=22445506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000614054A Expired - Fee Related JP4585693B2 (ja) 1999-04-22 2000-04-19 Ｉｉ型糖尿病を発現する危険性のｎｍｒによる決定方法

Country Status (9)

Country Link
US (1) US6518069B1 (ja)
EP (1) EP1171778B1 (ja)
JP (1) JP4585693B2 (ja)
AT (1) ATE319105T1 (ja)
AU (1) AU4469300A (ja)
CA (1) CA2367820C (ja)
DE (1) DE60026287T2 (ja)
ES (1) ES2256000T3 (ja)
WO (1) WO2000065366A1 (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7395158B2 (en) * 2000-05-30 2008-07-01 Sensys Medical, Inc. Method of screening for disorders of glucose metabolism
US20040236673A1 (en) * 2000-10-17 2004-11-25 Eder Jeff Scott Collaborative risk transfer system
CA2331116A1 (en) 2001-01-15 2002-07-15 Chenomx, Inc. Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system
CA2445106A1 (en) * 2001-04-23 2002-10-31 Metabometrix Limited Methods for analysis of spectral data and their applications: osteoporosis
US7901873B2 (en) 2001-04-23 2011-03-08 Tcp Innovations Limited Methods for the diagnosis and treatment of bone disorders
US20040162678A1 (en) * 2001-08-13 2004-08-19 Donald Hetzel Method of screening for disorders of glucose metabolism
ATE525635T1 (de) 2001-11-13 2011-10-15 Univ California Ionenmobilitätsanalyse biologischer partikel
EP1481356A1 (en) 2001-11-21 2004-12-01 Paradigm Genetics Inc. Methods and systems for analyzing complex biological systems
US6862592B1 (en) * 2001-12-21 2005-03-01 Adobe Systems Incorporated Document processing in a cross-platform environment
EP1329716A1 (en) * 2002-01-16 2003-07-23 Roche Diagnostics GmbH Method for screening biological samples for presence of the metabolic syndrome
US7426499B2 (en) * 2004-11-08 2008-09-16 Asset Trust, Inc. Search ranking system
US7730063B2 (en) * 2002-12-10 2010-06-01 Asset Trust, Inc. Personalized medicine service
US20080027769A1 (en) * 2002-09-09 2008-01-31 Jeff Scott Eder Knowledge based performance management system
US20070011049A1 (en) * 2005-07-09 2007-01-11 Eder Jeffrey S Intelligent, personalized commerce chain
US7243030B2 (en) * 2002-10-25 2007-07-10 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
DE10315877B4 (de) * 2003-04-08 2005-11-17 Roche Diagnostics Gmbh Krankheitsverlaufkontrolle
US8460243B2 (en) * 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
US7197427B2 (en) * 2004-03-31 2007-03-27 Genworth Financial Inc. Method for risk based testing
EP1735631A2 (en) * 2004-04-01 2006-12-27 Liposcience, Inc. Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
US7422224B2 (en) * 2004-04-13 2008-09-09 Kimir Seatpost Adjustable bicycle seat post assembly
CA3090413C (en) 2004-06-04 2023-10-10 Abbott Diabetes Care Inc. Glucose monitoring and graphical representations in a data management system
US7951078B2 (en) * 2005-02-03 2011-05-31 Maren Theresa Scheuner Method and apparatus for determining familial risk of disease
ATE412364T1 (de) 2005-03-15 2008-11-15 Hoffmann La Roche Verfahren und system zur untersuchung des glucosestoffwechsels
ES2522816T3 (es) * 2006-03-24 2014-11-18 Metanomics Gmbh Procedimiento para predecir la diabetes de tipo II
US8498915B2 (en) * 2006-04-02 2013-07-30 Asset Reliance, Inc. Data processing framework for financial services
US8247235B2 (en) 2007-06-08 2012-08-21 Quest Diagnostics Investments Incorporated Lipoprotein analysis by differential charged-particle mobility
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US9354200B1 (en) 2008-08-07 2016-05-31 Quest Diagnostics Investments Incorporated Detection apparatus for differential-charged particle mobility analyzer
US8386187B2 (en) * 2008-10-20 2013-02-26 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
DE102009026651A1 (de) 2009-06-02 2011-02-17 Großmann, Kay, Dr. rer. nat. (Chemie) Verfahren und Messvorrichtung zur qualitativen und quantitativen Analyse von Körperflüssigkeiten
US9250211B2 (en) 2010-12-30 2016-02-02 Quest Diagnostics Investments Incorporated Magnetic separation of lipoproteins using dextran sulfate
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
WO2012163361A1 (en) * 2011-05-31 2012-12-06 Aarhus Universitet Method and system for identification of physiological imbalance in an animal
EP2726857B1 (en) * 2011-06-30 2019-10-23 Liposcience, Inc. Quantitative nmr clinical analyzers with automatic nmr temperature sensitivity compensation that accommodate large ambient operational temperature ranges
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9551768B2 (en) 2013-03-15 2017-01-24 East Carolina University NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease
US20150260631A1 (en) * 2014-03-17 2015-09-17 Health Diagnostic Laboratory, Inc. System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions
DE102014203721B4 (de) * 2014-02-28 2018-12-27 Bruker Biospin Gmbh Verfahren zur Bestimmung der Konzentration einer Substanz in einer Probe
EP3210028A1 (en) 2014-10-21 2017-08-30 True Health IP LLC Lipoprotein particle number from measurements of lipoprotein particle phospholipid concentration in lipoprotein particle membrane bilayer
US20160109472A1 (en) 2014-10-21 2016-04-21 Health Diagnostic Laboratory, Inc. Quantitative molar concentration detection of specific apolipoprotein-containing particles present in bodily fluids by using capillary electrophoresis
EP3213088A1 (en) 2014-10-27 2017-09-06 True Health IP LLC Lp(a) subform size identification by capillary isoteachophoresis electrophoresis with laser-induced-fluorescence
US10654909B2 (en) 2014-12-04 2020-05-19 Novartis Ag Soluble alpha klotho and serum albumin fusion protein
JP7341987B2 (ja) * 2017-09-07 2023-09-11 リポサイエンス，インコーポレイテッド マルチパラメータ代謝脆弱性指数評価
US10775458B2 (en) 2018-03-05 2020-09-15 Texas Tech University System Method and system for non-invasive measurement of metabolic health
WO2023239869A1 (en) * 2022-06-09 2023-12-14 Quest Diagnostics Investments Llc Quantification of lipoprotein subfractions by ion mobility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4933844A (en) 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
BR9007936A (pt) 1989-12-21 1992-10-27 Beth Israel Hospital Processo para diagnosticar risco arterioscleroso,e processo de medicao de concentracoes de lipoproteina
AU2384292A (en) 1991-07-30 1993-03-02 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
US5585235A (en) * 1993-04-13 1996-12-17 Diagnescent Technologies, Inc. Fluorescent assay and method that corrects for spectral interference
NZ275054A (en) * 1993-11-08 1997-04-24 Peptide Delivery Systems Pty L Diagnosing atherosclerosis or coronary artery disease using labelled composition which mimics essential features of an exogenous lipoprotein
US5685300A (en) * 1994-04-01 1997-11-11 Kuenstner; J. Todd Noninvasive and in-vitro measurement of glucose and cholesterol by nuclear magnetic resonance spectroscopy
US6163154A (en) 1997-12-23 2000-12-19 Magnetic Diagnostics, Inc. Small scale NMR spectroscopic apparatus and method
US6226082B1 (en) 1998-06-25 2001-05-01 Amira Medical Method and apparatus for the quantitative analysis of a liquid sample with surface enhanced spectroscopy

Similar Documents

Publication Publication Date Title
JP2002534241A5 (ja)
JP2002543392A5 (ja)
JP2003519868A5 (ja)
JP2002027377A5 (ja)
JP2001094929A5 (ja)
JP2002018866A5 (ja)
JP2002090177A5 (ja)
JP2001014378A5 (ja)
JP2001190327A5 (ja)
JP2001067277A5 (ja)
JP2001358208A5 (ja)
JP2002043823A5 (ja)
JP2003518646A5 (ja)
JP2002099016A5 (ja)
JP2001245867A5 (ja)
CN300955183S (zh) 连接件
JP2002075627A5 (ja)
CN3135930S (ja)
CN3135584S (ja)
CN3139849S (ja)
CN3136619S (ja)
CN3139850S (ja)
CN3139852S (ja)
CN3137256S (ja)
CN3141398S (ja)